PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios

Biotech-2023

Last updated Sep 23, 2023

Asset Allocation


ISRG 33%ARWR 20%SAGE 14%TGTX 9%MREO 9%NTLA 9%ONCT 4%DTIL 2%EquityEquity
PositionCategory/SectorWeight
ISRG
Intuitive Surgical, Inc.
Healthcare33%
ARWR
Arrowhead Pharmaceuticals, Inc.
Healthcare20%
SAGE
Sage Therapeutics, Inc.
Healthcare14%
TGTX
TG Therapeutics, Inc.
Healthcare9%
MREO
Mereo BioPharma Group plc
Healthcare9%
NTLA
Intellia Therapeutics, Inc.
Healthcare9%
ONCT
Oncternal Therapeutics, Inc.
Healthcare4%
DTIL
Precision BioSciences, Inc.
Healthcare2%

Performance

The chart shows the growth of an initial investment of $10,000 in Biotech-2023, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Quarterly


0.00%10.00%20.00%30.00%40.00%AprilMayJuneJulyAugustSeptember
-2.81%
8.61%
Biotech-2023
Benchmark (^GSPC)
Portfolio components

Returns


1 month6 monthsYear-To-Date1 year5 years (annualized)10 years (annualized)
Benchmark-1.29%8.79%12.52%16.97%9.22%N/A
Biotech-2023-3.46%-3.31%-7.95%16.42%8.26%N/A
ARWR
Arrowhead Pharmaceuticals, Inc.
-2.85%12.14%-32.84%-11.93%8.58%N/A
SAGE
Sage Therapeutics, Inc.
-1.06%-54.42%-48.72%-49.19%-38.28%N/A
TGTX
TG Therapeutics, Inc.
-11.78%-37.82%-22.74%59.23%2.98%N/A
MREO
Mereo BioPharma Group plc
-3.57%71.21%80.00%60.39%-29.97%N/A
ONCT
Oncternal Therapeutics, Inc.
-8.97%-64.46%-68.96%-62.48%-52.09%N/A
NTLA
Intellia Therapeutics, Inc.
-13.67%-15.43%-7.17%-39.93%16.23%N/A
DTIL
Precision BioSciences, Inc.
-23.92%-45.66%-68.03%-68.82%-54.91%N/A
ISRG
Intuitive Surgical, Inc.
0.90%12.39%8.61%51.27%12.80%N/A

Asset Correlations Table

The table below shows the correlation coefficients between the assets in the portfolio.

MREOONCTISRGDTILSAGETGTXARWRNTLA
MREO1.000.200.190.220.250.240.290.26
ONCT0.201.000.190.260.290.260.280.25
ISRG0.190.191.000.310.360.420.400.44
DTIL0.220.260.311.000.410.410.410.49
SAGE0.250.290.360.411.000.470.470.47
TGTX0.240.260.420.410.471.000.520.55
ARWR0.290.280.400.410.470.521.000.53
NTLA0.260.250.440.490.470.550.531.00

Sharpe Ratio

The current Biotech-2023 Sharpe ratio is 0.28. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.

-1.000.001.002.003.004.000.28

The Sharpe ratio of Biotech-2023 is in the bottom 25%, suggesting that this portfolio isn't performing as well in terms of risk-adjusted returns compared to many others. This could be due to lower returns, higher volatility, or both. It might be an indication that the portfolio needs fine-tuning.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.00AprilMayJuneJulyAugustSeptember
0.28
0.81
Biotech-2023
Benchmark (^GSPC)
Portfolio components

Dividend yield


Biotech-2023 doesn't pay dividends

Expense Ratio

The Biotech-2023 has an expense ratio of 0.00%, indicating no management fees are charged. Below you can find the expense ratios of portfolio funds side-by-side and effortlessly compare their relative costs.


The portfolio doesn't hold funds that charge fees

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for positions. Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ARWR
Arrowhead Pharmaceuticals, Inc.
-0.27
SAGE
Sage Therapeutics, Inc.
-0.69
TGTX
TG Therapeutics, Inc.
0.33
MREO
Mereo BioPharma Group plc
0.42
ONCT
Oncternal Therapeutics, Inc.
-0.63
NTLA
Intellia Therapeutics, Inc.
-0.82
DTIL
Precision BioSciences, Inc.
-0.97
ISRG
Intuitive Surgical, Inc.
1.46

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%AprilMayJuneJulyAugustSeptember
-49.12%
-9.93%
Biotech-2023
Benchmark (^GSPC)
Portfolio components

Worst Drawdowns

The table below shows the maximum drawdowns of the Biotech-2023. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Biotech-2023 is 62.53%, recorded on May 11, 2022. The portfolio has not recovered from it yet.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-62.53%Jul 2, 2021217May 11, 2022
-51.27%Dec 2, 201974Mar 18, 202084Jul 17, 2020158
-18.21%Jan 15, 202135Mar 8, 202167Jun 11, 2021102
-15.2%Aug 22, 201929Oct 2, 201922Nov 1, 201951
-9.51%Sep 3, 20203Sep 8, 20206Sep 16, 20209

Volatility Chart

The current Biotech-2023 volatility is 6.56%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%AprilMayJuneJulyAugustSeptember
6.56%
3.41%
Biotech-2023
Benchmark (^GSPC)
Portfolio components